{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:08:52Z","timestamp":1791328132443,"version":"4.3.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.eururo.2009.11.023","type":"journal-article","created":{"date-parts":[[2009,11,14]],"date-time":"2009-11-14T10:03:52Z","timestamp":1258193032000},"page":"410-429","source":"Crossref","is-referenced-by-count":161,"title":["The Role of Bacillus Calmette-Gu\u00e9rin in the Treatment of Non\u2013Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"57","author":[{"given":"Paolo","family":"Gontero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bohle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Uno","family":"Malmstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Oderda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2009.11.023_bib1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.biopha.2007.05.004","article-title":"Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement","volume":"61","author":"Brandau","year":"2007","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.eururo.2009.11.023_bib2","first-page":"1","article-title":"Methodological bases for systematic reviews","volume":"15","author":"Galfano","year":"2008","journal-title":"J Androl Sci"},{"key":"10.1016\/j.eururo.2009.11.023_bib3","unstructured":"Phillips B, Ball C, Sackett D, et al. Levels of evidence. Oxford Centre for Evidence-based Medicine Web site. http:\/\/www.cebm.net\/levels_of_evidence.asp. Updated March 2009."},{"key":"10.1016\/j.eururo.2009.11.023_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib5","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib8","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2009.11.023_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","article-title":"Modified induction course: a solution to side-effects?","volume":"37","author":"Bassi","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000020170","article-title":"What is the optimal regimen for BCG intravesical therapy? Are six week instillations necessary?","volume":"37","author":"Zlotta","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2005.05.004","article-title":"BCG dose reduction by decreasing the instillation frequency: effects on local Th1\/Th2 cytokine responses in a mouse model","volume":"48","author":"De Boer","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0090-4295(97)00067-8","article-title":"Additional bacillus Calmette-Gu\u00e9rin therapy for recurrent transitional cell carcinoma after an initial complete response","volume":"49","author":"Bui","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer\u2014Genito-Urinary Group phase III trial","volume":"173","author":"De Reijke","year":"2005","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2009.11.023_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib18","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","article-title":"Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects","volume":"96","author":"Andius","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.11.023_bib19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2009.11.023_bib20","first-page":"2672","article-title":"Antibody responses to bacillus Calmette-Gu\u00e9rin during immunotherapy in bladder cancer patients","volume":"41","author":"Winters","year":"1981","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2009.11.023_bib21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Gu\u00e9rin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.eururo.2008.06.062","article-title":"Is maintenance bacillus Calmette-Gu\u00e9rin really necessary?","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib26","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumor-recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.11.023_bib28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib29","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non\u2013muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/01.coc.0000135570.37287.7f","article-title":"The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a meta-analytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy","volume":"27","author":"Huncharek","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2009.11.023_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","article-title":"Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours","volume":"41","author":"Patard","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","article-title":"Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?","volume":"172","author":"Thalmann","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mytomicin-C and bacillus Calmette-Gu\u00e9rin in patients with high-risk bladder cancer","volume":"99","author":"Gardmark","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.11.023_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","article-title":"Intravesical bacille Calmette-Gu\u00e9rin in stage 1 grade 3 bladder cancer therapy: a 7-year follow-up","volume":"54","author":"Hurle","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0090-4295(98)00369-0","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder","volume":"52","author":"Baniel","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib41","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","article-title":"Tumour progression and survival in patients with T1G3 bladder tumours: 15-years outcome","volume":"80","author":"Herr","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1474-9728.2004.00106.x","article-title":"Immunity and aging: the enemy within?","volume":"3","author":"DeVeale","year":"2004","journal-title":"Aging Cell"},{"key":"10.1016\/j.eururo.2009.11.023_bib45","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2009.11.023_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2009.11.023_bib47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000052381","article-title":"BCG intravesical instillations: recommendations for side-effects management","volume":"37","author":"Rischmann","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib48","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0022-5347(06)00264-3","article-title":"Complications of intravesical therapy for urothelial cancer of the bladder","volume":"175","author":"Koya","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1442-2042.2005.01000.x","article-title":"Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder","volume":"12","author":"Koga","year":"2005","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib51","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1086\/344908","article-title":"Spectrum of bacille Calmette-Gu\u00e9rin (BCG) infection after intravesical BCG immunotherapy","volume":"36","author":"Gonzalez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eururo.2009.11.023_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urolonc.2007.04.005","article-title":"Effect of advanced age on the development of complications from intravesical bacillus Calmette-Gu\u00e9rin therapy","volume":"26","author":"Heiner","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2009.11.023_bib54","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/01.ju.0000059681.67567.12","article-title":"The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin","volume":"169","author":"Bilen","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib55","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"Van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib56","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"ITB01 Study Group. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib57","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/ncpuro0781","article-title":"Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?","volume":"4","author":"O\u2019Donnell","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib58","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1464-410X.2003.04764.x","article-title":"Bacillus Calmette-Gu\u00e9rin therapy in stage Ta\/T1 bladder cancer: prognostic factors for time to recurrence and progression","volume":"93","author":"Andius","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.11.023_bib59","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/01.TP.0000090748.32764.0F","article-title":"Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients","volume":"76","author":"Palou","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.eururo.2009.11.023_bib60","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.juro.2006.03.066","article-title":"Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients","volume":"176","author":"Yossepowitch","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib61","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy\u2013associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2009.11.023_bib62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/1561095021000037631","article-title":"Use of BCG in immunotherapy of superficial bladder cancer: multicentric investigation on safety and compliance","volume":"2","author":"Morgia","year":"2003","journal-title":"Urooncology"},{"key":"10.1016\/j.eururo.2009.11.023_bib63","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazide reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 303911","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib64","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","article-title":"Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results","volume":"163","author":"Losa","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2009.11.023_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000475204","article-title":"Improving the efficacy of BCG immunotherapy by dose reduction","volume":"27","author":"Pagano","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000241663","article-title":"Methodology of superficial bladder cancer trials: objective evaluation of treatment \u2013 the need for standardization","volume":"83","author":"Bassi","year":"2009","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2009.11.023_bib67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.11.023_bib69","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","article-title":"The safety and efficacy of different doses of bacillus Calmette-Gu\u00e9rin in superficial bladder transitional cell carcinoma","volume":"70","author":"Agrawal","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2009.11.023_bib71","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/00365590410028692","article-title":"Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Gu\u00e9rin","volume":"38","author":"Andius","year":"2004","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2009.11.023_bib72","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2003.11.011","article-title":"Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1)","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib73","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000020233","article-title":"Prognostic value of MIB-1 antibody labelling index to predict response to Bacillus Calmette-Gu\u00e9rin therapy in high-risk selected population of patients with stage T1 grade G3 bladder cancer","volume":"37","author":"Lebret","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib74","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0090-4295(01)01551-5","article-title":"Prognostic value of P53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Gu\u00e9rin therapy","volume":"59","author":"Peyromaure","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib75","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2003.11.018","article-title":"Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette-Gu\u00e9rin (BCG)","volume":"45","author":"Saint","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib76","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.22503","article-title":"Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha","volume":"109","author":"Esuvaranathan","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2009.11.023_bib77","doi-asserted-by":"crossref","unstructured":"Cormio L, Tolve I, Annese P, et al. Retinoblastoma protein expression predicts response to bacillus Calmette-Gu\u00e9rin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol. In press. doi:10.1016\/j.urolonc.2008.08.003.","DOI":"10.1016\/j.urolonc.2008.08.003"},{"key":"10.1016\/j.eururo.2009.11.023_bib78","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib79","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-5347(05)64361-3","article-title":"Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer","volume":"168","author":"Kumar","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Gu\u00e9rin failure pattern on subsequent response to bacille Calmette-Gu\u00e9rin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib81","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2B for superficial bladder cancer","volume":"172","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib82","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","article-title":"Bacillus Calmette-Gu\u00e9rin plus interferon-\u03b12B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity","volume":"21","author":"Lam","year":"2003","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2009.11.023_bib83","first-page":"1790","article-title":"Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy","volume":"10","author":"Punnen","year":"2003","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib84","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-\u03b12B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib85","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0090-4295(01)01187-6","article-title":"Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach","volume":"58","author":"Luciani","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.11.023_bib86","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1442-2042.2000.00176.x","article-title":"Clinical experience with BCG alone versus BCG plus epirubicin","volume":"7","author":"Bilen","year":"2000","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000051005","article-title":"Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Gu\u00e9rin is not contraindicated for superficial bladder cancer","volume":"67","author":"Tozawa","year":"2001","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2009.11.023_bib88","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.juro.2008.03.038","article-title":"Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study","volume":"180","author":"Cai","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib89","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin alone in patients with superficial bladder cancer","volume":"160","author":"Witjes","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib90","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(05)67446-0","article-title":"Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-\u03b12B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma","volume":"164","author":"Kaasinen","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib91","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of urinary bladder: a Nordic study","volume":"43","author":"Kaasinen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.11.023_bib92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809011658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809011658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T21:07:01Z","timestamp":1558645621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283809011658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0302283809011658"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2009.11.023","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}